Which Are The Top Ten BioPharma Companies?
2 CommentsBy Ed Silverman // July 23rd, 2008 // 3:06 pm
Depends who you ask. But Contract Pharma magazine decided that a biopharma company is one that makes more than 40 percent of its drug revenues by selling biologic products, including biotherapeutics, vaccines and other proteins. As the mag’s editor, Gil Roth, says: No royalty-based companies allowed! (That means you, ImClone). This can be limiting, though. Gil could only find nine companies that would qualify for his Top 10 list. So to round it off, he threw in Elan, since it co-markets Tysabri with Biogen Idec. Good editors think creatively.
1 - Amgen - $14.3 billion
2 - Genentech - $9.4 billion
3 - Novo Nordisk - $7.7 billion
4 - Merck Serono - $6.1 billion
5 - Baxter BioScience - $4.6 billion
6 - Biogen Idec - $3.1 billion
7 - Genzyme - $2.8 billion
8 - CSL - $2.3 billion
9 - Allergan - $1.2 billion
10 - Elan - $446 million
Based on 2007 biopharma revenues only. If you want to read about each company, please look here.
Jeffrey Clark, CEO of Beaker.com - The Online Community for Life Sciences Professionals
In this environment, hold onto your hat. At Beaker, we are constantly trying to track the leading companies in medical devices, pharmaceuticals, biotechnology & the like. Well, with the rash of recent M&A activity, its tough to stay up to date.
Imagine the answer to this question just a few years ago: Amgen, Genentech, Immunex, Chiron, etc. It never ceases to amaze how the profile of this young industry changes so quickly. The question is: Will the biotechnology industry lose its identity if its biggest & most successful players continue to get merged into more traditional corporate structures?
Pharma Whore
Jeffrey - I concur with your comments on the ever changing status of the industry. As we know from history, it will repeat itself. What gets larger will spawn the new cutting edge thoughts and companies. This is what keeps innovation alive.
The industry will not remain static, it will evolve into a new animal. It is up to individuals and how they want their culture to be. This culture that we have in Biotech will relect those who are the sum of its parts.
Only the future knows, let’s revisit this question in another 5 years and see how it all plays out.